Kate Groot

5.8k total citations
143 papers, 4.9k citations indexed

About

Kate Groot is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Epidemiology. According to data from OpenAlex, Kate Groot has authored 143 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Endocrinology, Diabetes and Metabolism, 37 papers in Molecular Biology and 29 papers in Epidemiology. Recurrent topics in Kate Groot's work include Growth Hormone and Insulin-like Growth Factors (76 papers), Neuroendocrine Tumor Research Advances (29 papers) and Neuropeptides and Animal Physiology (23 papers). Kate Groot is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (76 papers), Neuroendocrine Tumor Research Advances (29 papers) and Neuropeptides and Animal Physiology (23 papers). Kate Groot collaborates with scholars based in United States, Hungary and India. Kate Groot's co-authors include Andrew V. Schally, Károly Szepesházi, Gábor Halmos, Patricia Armatis, György B. Halmos, József L. Varga, J. Pinski, A. Jungwirth, Attila Nagy and Judit Horváth and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Clinical Endocrinology & Metabolism and JNCI Journal of the National Cancer Institute.

In The Last Decade

Kate Groot

143 papers receiving 4.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kate Groot United States	44	2.3k	1.5k	1.4k	904	796	143	4.9k
Gábor Halmos United States	41	1.8k 0.8×	1.8k 1.2×	1.8k 1.3×	1.1k 1.2×	655 0.8×	163	5.0k
Károly Szepesházi United States	35	941 0.4×	1.1k 0.7×	1.2k 0.9×	821 0.9×	474 0.6×	96	3.1k
Cornelis J.M. Lips Netherlands	37	1.5k 0.6×	1.8k 1.2×	960 0.7×	913 1.0×	713 0.9×	96	4.5k
Jo W.M. Höppener Netherlands	37	1.6k 0.7×	2.9k 1.9×	1.1k 0.8×	918 1.0×	858 1.1×	92	5.8k
A H Tashjian United States	39	1.4k 0.6×	2.3k 1.5×	942 0.7×	426 0.5×	491 0.6×	86	4.8k
Masanobu Yamada Japan	31	1.7k 0.7×	1.1k 0.7×	435 0.3×	329 0.4×	437 0.5×	208	3.7k
G I Bell United States	31	1.4k 0.6×	4.0k 2.6×	603 0.4×	1.2k 1.4×	1.1k 1.4×	55	6.4k
Michael Karl United States	40	1.6k 0.7×	3.2k 2.0×	403 0.3×	156 0.2×	1.1k 1.4×	109	6.1k
Jasmine Parma Belgium	35	2.6k 1.1×	2.3k 1.5×	432 0.3×	145 0.2×	692 0.9×	66	4.7k
Coimbatore B. Srikant Canada	38	1.3k 0.6×	2.2k 1.4×	800 0.6×	2.2k 2.4×	235 0.3×	73	4.6k

Countries citing papers authored by Kate Groot

Since Specialization

Citations

This map shows the geographic impact of Kate Groot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kate Groot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kate Groot more than expected).

Fields of papers citing papers by Kate Groot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kate Groot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kate Groot. The network helps show where Kate Groot may publish in the future.

Co-authorship network of co-authors of Kate Groot

This figure shows the co-authorship network connecting the top 25 collaborators of Kate Groot. A scholar is included among the top collaborators of Kate Groot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kate Groot. Kate Groot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bannier, Michiel, Hettie M. Janssens, Peter Merkus, et al.. (2025). Introduction of Ivacaftor/Lumacaftor in Children With Cystic Fibrosis Homozygous for F508del in the Netherlands: A Nationwide Real‐Life Study. Pediatric Pulmonology. 60(1). e27473–e27473. 1 indexed citations

Zarándi, Márta, József L. Varga, Andrew V. Schally, et al.. (2006). Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities. Proceedings of the National Academy of Sciences. 103(12). 4610–4615. 20 indexed citations

Havt, Alexandre, Andrew V. Schally, Gábor Halmos, et al.. (2005). The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proceedings of the National Academy of Sciences. 102(48). 17424–17429. 101 indexed citations

Schally, Andrew V., et al.. (2003). Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumour growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers. European Journal of Cancer. 40(3). 436–444. 11 indexed citations

Schally, Andrew V., et al.. (2003). The Expression of Growth Hormone-Releasing Hormone (GHRH) and its Receptor Splice Variants in Human Breast Cancer Lines; The Evaluation of Signaling Mechanisms in the Stimulation of Cell Proliferation. Breast Cancer Research and Treatment. 77(1). 15–26. 49 indexed citations

Schally, Andrew V., Artur Płonowski, József L. Varga, et al.. (2002). Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK‐ES‐1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone‐releasing hormone. Cancer. 95(8). 1735–1745. 46 indexed citations

Sun, Baodong, et al.. (2000). Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II. Cancer. 88(6). 1384–1392. 21 indexed citations

Nagy, Attila, et al.. (1999). Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238. International Journal of Cancer. 82(4). 592–598. 39 indexed citations

Schally, Andrew V., et al.. (1998). GRHきっ坑薬のMZ‐5‐156は,ヌードマウスのDU‐145ヒトアンドロゲン非依存性前立腺癌の成長を阻害し,腫よう内のIGF2のレベル及びmRNA発現を低下させる. Proc Natl Acad Sci USA. 95(15). 8864–8868. 50 indexed citations

10.

Jungwirth, A., et al.. (1998). Inhibition of the growth of caki-I human renal adenocarcinoma in Vivo by luteinizing hormone-releasing hormone antagonist cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II. Cancer. 82(5). 909–917. 27 indexed citations

11.

Jungwirth, A., Andrew V. Schally, J. Pinski, et al.. (1997). Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. British Journal of Cancer. 75(11). 1585–1592. 76 indexed citations

12.

Pinski, J., Najib Lamharzi, György B. Halmos, et al.. (1996). Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats.. Endocrinology. 137(8). 3430–3436. 60 indexed citations

13.

Szepesházi, Károly, Andrew V. Schally, Gábor Halmos, et al.. (1996). Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogendependent MXT mouse mammary cancers: Correlations between growth characteristics and EGF receptor content of tumors. Breast Cancer Research and Treatment. 40(2). 129–139. 10 indexed citations

14.

Pinski, J., Andrew V. Schally, A. Jungwirth, et al.. (1996). Inhibition of growth of human small cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH). International Journal of Oncology. 9(6). 1099–1105. 56 indexed citations

15.

Pinski, J., Andrew V. Schally, Kate Groot, et al.. (1995). Inhibition of Growth of Human Osteosarcomas by Antagonists of Growth Hormone-Releasing Hormone. JNCI Journal of the National Cancer Institute. 87(23). 1787–1794. 84 indexed citations

16.

Pinski, J., Andrew V. Schally, T. Yano, et al.. (1995). Evaluation of the in vitro and in vivo activity of the l‐, d,l‐ and d‐Cit⁶ forms of the LH‐RH antagonist Cetrorelix (SB‐75). International journal of peptide & protein research. 45(5). 410–417. 9 indexed citations

17.

Schally, Andrew V., Károly Szepesházi, György B. Halmos, et al.. (1994). Antitumor effects of analogs of somatostatin and antagonists of bombesin/GRP in experimental models of pancreatic cancer. University of Debrecen Electronic Archive (University of Debrecen). 16. 246–249. 3 indexed citations

18.

Pinski, Jacek, Tetsu Yano, Károly Szepesházi, Kate Groot, & Andrew V. Schally. (1993). Recovery of Pituitary‐Gonadal Function in Male Rats after Long‐Term Suppression Induced by a Single Injection of Microcapsules of LH‐RH Antagonist Cetrorelix (SB‐75). Journal of Andrology. 14(3). 164–169. 12 indexed citations

19.

Schally, Andrew V., Tommie W. Redding, Kate Groot, et al.. (1991). Isolation and characterization of two peptides with prolactin release-inhibiting activity from porcine hypothalami.. Proceedings of the National Academy of Sciences. 88(9). 3540–3544. 10 indexed citations

20.

Iwasaki, Kengo, Ayako Fujii, Akira Arimura, & Kate Groot. (1989). Suppression of testicular activity by a GnRH agonist in hypophysectomized, gonadotropin-treated mice.. PubMed. 14(1). 25–8. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact